Abo Bibliothek: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Erscheint 6 Ausgaben pro Jahr

ISSN Druckformat: 0743-4863

ISSN Online: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Small RNAs: The Qualified Candidates for Gene Manipulation in Diverse Clinical Pathologies

Volumen 31, Ausgabe 4, 2014, pp. 305-329
DOI: 10.1615/CritRevTherDrugCarrierSyst.2014007943
Get accessGet access

ABSTRAKT

In recent years, RNA interference (RNAi) has become a tool of choice to analyze and target the in vitro and in vivo function of mammalian genes. RNAi down-regulates gene expression by inducing enzyme-dependent degradation of targeted mRNA. This can be achieved using small double-stranded RNAs (dsRNAs), including small interfering RNAs (siRNAs), micro RNAs, and piwi RNAs. These active, small dsRNAs can regulate endogenous genes in both somatic and germ cells such that they can defend the genome from invasive nucleic acids. Extension of the concept of RNAi to preclinical studies indicates its probable application in the treatment of cancers, viral infections, arterial stenosis, and genetic disorders. Exciting results from ongoing clinical trials have raised the expectations of the scientific community for the use of RNAi in "real cures". Rational pharmaceutical design of these molecules can further open a Pandora's box of newer therapeutic options. However, efficient delivery of these small dsRNAs to target tissues or cells and their unanticipated nonspecific effects comprise a few important issues that still need to be addressed. In this review, we offer an overview of different small dsRNAs, their biogenesis, and their applicability in therapeutics. Current delivery strategies and formulation techniques to achieve the desired transfection capability and RNAi products in clinical trials are also discussed.

REFERENZIERT VON
  1. Lacko Andras G., Sabnis Nirupama A., Nagarajan Bhavani, McConathy Walter J., HDL as a drug and nucleic acid delivery vehicle, Frontiers in Pharmacology, 6, 2015. Crossref

  2. Kaur Indu Pal, Sharma Gaurav, Singh Mandeep, Sandhu Simarjot Kaur, Deol Parneet K., Yadav Monika, Yakhmi Jatinder Vir, Nanobiomaterials as gene-delivery vehicles, in Nanobiomaterials in Drug Delivery, 2016. Crossref

  3. Li Yanfeng , Gao Wenbo , Ma Yan , Zhu Guanyu , Chen Fuhui , Qu Hongyan , Dual targeting of survivin and X‑linked inhibitor of apoptosis protein suppresses the growth and promotes the apoptosis of gastric cancer HGC‑27 cells , Oncology Letters, 2018. Crossref

  4. Holsæter Ann Mari, Wizgird Kristina, Karlsen Iselin, Hemmingsen Jeanette Frimand, Brandl Martin, Škalko-Basnet Nataša, How docetaxel entrapment, vesicle size, zeta potential and stability change with liposome composition–A formulation screening study, European Journal of Pharmaceutical Sciences, 177, 2022. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain